KarXT Schizophrenia Win; CBD for Anxiety; No Nuplazid for Alzheimer's Psychosis

(MedPage Today) -- The phase III EMERGENT-2 trial met its primary endpoint achieving a significant reduction in PANSS total score with oral KarXT (xanomeline-trospium) versus placebo in people with schizophrenia, Karuna Therapeutics announced...
Source: MedPage Today Psychiatry - Category: Psychiatry Source Type: news